Literature DB >> 24658694

Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis.

Jeffrey K Lee, Elizabeth G Liles, Stephen Bent, Theodore R Levin, Douglas A Corley.   

Abstract

BACKGROUND: Performance characteristics of fecal immunochemical tests (FITs) to screen for colorectal cancer (CRC) have been inconsistent.
PURPOSE: To synthesize data about the diagnostic accuracy of FITs for CRC and identify factors affecting its performance characteristics. DATA SOURCES: Online databases, including MEDLINE and EMBASE, and bibliographies of included studies from 1996 to 2013. STUDY SELECTION: All studies evaluating the diagnostic accuracy of FITs for CRC in asymptomatic, average-risk adults. DATA EXTRACTION: Two reviewers independently extracted data and critiqued study quality. DATA SYNTHESIS: Nineteen eligible studies were included and meta-analyzed. The pooled sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of FITs for CRC were 0.79 (95% CI, 0.69 to 0.86), 0.94 (CI, 0.92 to 0.95), 13.10 (CI, 10.49 to 16.35), 0.23 (CI, 0.15 to 0.33), respectively, with an overall diagnostic accuracy of 95% (CI, 93% to 97%). There was substantial heterogeneity between studies in both the pooled sensitivity and specificity estimates. Stratifying by cutoff value for a positive test result or removal of discontinued FIT brands resulted in homogeneous sensitivity estimates. Sensitivity for CRC improved with lower assay cutoff values for a positive test result (for example, 0.89 [CI, 0.80 to 0.95] at a cutoff value less than 20 µg/g vs. 0.70 [CI, 0.55 to 0.81] at cutoff values of 20 to 50 µg/g) but with a corresponding decrease in specificity. A single-sample FIT had similar sensitivity and specificity as several samples, independent of FIT brand. LIMITATIONS: Only English-language articles were included. Lack of data prevented complete subgroup analyses by FIT brand.
CONCLUSION: Fecal immunochemical tests are moderately sensitive, are highly specific, and have high overall diagnostic accuracy for detecting CRC. Diagnostic performance of FITs depends on the cutoff value for a positive test result. PRIMARY FUNDING SOURCE: National Institute of Diabetes and Digestive and Kidney Diseases and National Cancer Institute.

Entities:  

Mesh:

Year:  2014        PMID: 24658694      PMCID: PMC4189821          DOI: 10.7326/M13-1484

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  53 in total

Review 1.  Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening.

Authors:  Linda Rabeneck; R Bryan Rumble; Frank Thompson; Michael Mills; Curtis Oleschuk; Alexandra Whibley; Hans Messersmith; Nancy Lewis
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

2.  Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary.

Authors:  Ba' Pham; Terry P Klassen; Margaret L Lawson; David Moher
Journal:  J Clin Epidemiol       Date:  2005-08       Impact factor: 6.437

Review 3.  The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies.

Authors:  Andra Morrison; Julie Polisena; Don Husereau; Kristen Moulton; Michelle Clark; Michelle Fiander; Monika Mierzwinski-Urban; Tammy Clifford; Brian Hutton; Danielle Rabb
Journal:  Int J Technol Assess Health Care       Date:  2012-04       Impact factor: 2.188

4.  Estimation of the optimal cut off point in a new immunological faecal occult blood test in a corporate colorectal cancer screening programme.

Authors:  M Itoh; K Takahashi; H Nishida; K Sakagami; T Okubo
Journal:  J Med Screen       Date:  1996       Impact factor: 2.136

5.  Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice.

Authors:  D K Rex; E Y Rahmani; J H Haseman; G T Lemmel; S Kaster; J S Buckley
Journal:  Gastroenterology       Date:  1997-01       Impact factor: 22.682

6.  A quantitative immunochemical fecal occult blood test for colorectal neoplasia.

Authors:  Zohar Levi; Paul Rozen; Rachel Hazazi; Alex Vilkin; Amal Waked; Eran Maoz; Shlomo Birkenfeld; Moshe Leshno; Yaron Niv
Journal:  Ann Intern Med       Date:  2007-02-20       Impact factor: 25.391

7.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

Authors:  J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

8.  Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.

Authors:  Hermann Brenner; Sha Tao
Journal:  Eur J Cancer       Date:  2013-05-22       Impact factor: 9.162

9.  Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.

Authors:  James E Allison; Lori C Sakoda; Theodore R Levin; Jo P Tucker; Irene S Tekawa; Thomas Cuff; Mary Pat Pauly; Lyle Shlager; Albert M Palitz; Wei K Zhao; J Sanford Schwartz; David F Ransohoff; Joseph V Selby
Journal:  J Natl Cancer Inst       Date:  2007-09-25       Impact factor: 13.506

10.  New occurrence and recurrence of neoplasms within 5 years of a screening colonoscopy.

Authors:  Benjamin Avidan; Amnon Sonnenberg; Thomas G Schnell; Jack Leya; Adrienne Metz; Stephen J Sontag
Journal:  Am J Gastroenterol       Date:  2002-06       Impact factor: 10.864

View more
  198 in total

1.  'Simple and easy:' providers' and latinos' perceptions of the fecal immunochemical test (FIT) for colorectal cancer screening.

Authors:  Claudia X Aguado Loi; Dinorah Martinez Tyson; Enmanuel A Chavarria; Liliana Gutierrez; Lynne Klasko; Stacy Davis; Diana Lopez; Tracy Johns; Cathy D Meade; Clement K Gwede
Journal:  Ethn Health       Date:  2018-01-10       Impact factor: 2.772

Review 2.  Evaluation of the Effectiveness and Cost-Effectiveness of Personalized Surveillance After Colorectal Adenomatous Polypectomy.

Authors:  Ethna McFerran; James F O'Mahony; Richard Fallis; Duncan McVicar; Ann G Zauber; Frank Kee
Journal:  Epidemiol Rev       Date:  2017-01-01       Impact factor: 6.222

3.  Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue.

Authors:  Theodore R Levin; Douglas A Corley; Christopher D Jensen; Amy R Marks; Wei K Zhao; Alexis M Zebrowski; Virginia P Quinn; Lawrence W Browne; William R Taylor; David A Ahlquist; Graham P Lidgard; Barry M Berger
Journal:  Dig Dis Sci       Date:  2017-01-02       Impact factor: 3.199

Review 4.  Stool Based Testing for Colorectal Cancer: an Overview of Available Evidence.

Authors:  Kevin M Rank; Aasma Shaukat
Journal:  Curr Gastroenterol Rep       Date:  2017-08

5.  Does Low Threshold Value Use Improve Proximal Neoplasia Detection by Fecal Immunochemical Test?

Authors:  Nam Hee Kim; Hyo-Joon Yang; Soo-Kyung Park; Jung Ho Park; Dong Il Park; Chong Il Sohn; Kyuyong Choi; Yoon Suk Jung
Journal:  Dig Dis Sci       Date:  2016-04-23       Impact factor: 3.199

6.  What is the optimal colorectal cancer screening program for an average-risk population?

Authors:  Masau Sekiguchi; Takahisa Matsuda; Yutaka Saito
Journal:  Transl Gastroenterol Hepatol       Date:  2017-03-16

7.  Systematic review: Gut microbiota in fecal samples and detection of colorectal neoplasms.

Authors:  Efrat L Amitay; Agne Krilaviciute; Hermann Brenner
Journal:  Gut Microbes       Date:  2018-05-15

Review 8.  Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Douglas J Robertson; Jeffrey K Lee; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas K Rex
Journal:  Am J Gastroenterol       Date:  2016-10-18       Impact factor: 10.864

9.  Nonsteroidal Anti-Inflammatory Drug-Induced Colopathy in a Colorectal Cancer Screening Program.

Authors:  Sanja Borozan; Ljiljana Vuckovic; Brigita Smolovic
Journal:  Med Princ Pract       Date:  2018-10-25       Impact factor: 1.927

10.  Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.

Authors:  Uri Ladabaum; Ajitha Mannalithara; Joel V Brill; Zachary Levin; Kate M Bundorf
Journal:  Am J Gastroenterol       Date:  2018-06-15       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.